#ESMO22 Presidential Symposium 1 LBA3 TIL vs ipilimumab for advanced melanoma, phase 3 study @HaanenJohn @OncoAlert @myESMO
Unresectable stage IIC-IV melanoma progression with a max of 1 line of prior systemic treatment (not ipi), N = 168, randomized 1:1 TIL vs ipilimumab. Primary EP = PFS; Most pts had prior anti PD-1 treatment 
PFS significantly improved with TIL vs ipi (Median PFS: 7.2 vs 3.1 mo). HR = 0.50, P < .001. The majority of predefined subgroups benefited from TIL
Best ORR 48.8% vs 21.4% with 20.2% CR with TIL vs 7.1 mo with ipi and CBR of 67.9% vs 39.3%
OS was not significantly improved and longer follow up is needed although the study was not powered to detect OS
All patients had grade 3 or higher AE with different TEAES attributed to CT and TIL + IL2
Significantly improved overall health-related QOL scores with TIL vs ipi
Overall, TIL significantly improved PFS compared with ipilimumab in pts with advanced melanoma as first or 2nd line treatment in a largely anti-PD-1 refractory patient population
• • •
Missing some Tweet in this thread? You can try to
force a refresh
